Research peptides
SEMAX
Available documentary data and items still to verify are detailed below.
Price incl. VAT€58.00
AvailabilityAvailable
SKUsemax
Loading availability…
02 — Information to verify
Product details
Overview
Semax is a synthetic heptapeptide with sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its structure is described as the ACTH(4–7) fragment followed by Pro-Gly-Pro; it is not full-length ACTH.
Structure and technical data
Technical data
Format: 10 mg. Sequence: MEHFPGP. PubChem CID 9811102 lists formula C37H51N9O10S and mass 813.9 g/mol. The reference describes non-acetylated Semax without assigning modified variants.
- Sequence
- MEHFPGP
- Molecular formula
- C37H51N9O10S
- Reported molecular mass
- 813.9 g/mol
- CAS number
- 80714-61-0
- PubChem CID
- 9811102
- Reported synonyms
- Semax; ACTH(4–7)-Pro-Gly-Pro
Reference molecular data.
Research context
The cited papers analyse immune-response gene expression and protein profiles in rat models of cerebral ischaemia.
From ACTH to the MEHFPGP peptideCerebral ischaemia: transcripts and proteinsImmune pathways and tissue-stress responsesSeizure models and oxidative markersBrain networks and functional imagingAcute stress, behaviour, and early-life models
From ACTH to the MEHFPGP peptide
Met-Glu-His-Phe corresponds to ACTH(4–7), followed by Pro-Gly-Pro. This construction distinguishes Semax from full ACTH and analogues with acetylation or terminal changes. The nootropic designation describes a research area, not proven cognitive improvement from every material bearing the name.
Cerebral ischaemia: transcripts and proteins
Rat models compare immune-gene expression, proinflammatory transcripts, and protein profiles after ischaemia and reperfusion. Transcriptomics and proteomics observe different response levels. Agreement between some signals supports mechanistic hypotheses without turning the model into clinical evidence for the product.
10.1007/s00438-017-1297-1 10.1134/S0026893321010040 10.3390/ijms22126179
Immune pathways and tissue-stress responses
Research analyses inflammatory mediators and cellular programmes activated after brain injury. Changes in immunoglobulin-related or immune-cell pathways are molecular model readouts. They do not demonstrate general immune enhancement or independently establish which cells generate each signal.
Seizure models and oxidative markers
The bibliography includes a conference paper on rat malondialdehyde and protein profiles and a study of audiogenic-seizure susceptibility across mouse strains. Observed effects depend on strain and exposure timing. These models do not establish clinical efficacy in human epilepsy.
Brain networks and functional imaging
The default-mode-network paper uses resting-state functional imaging in a small healthy-volunteer sample. It reports a difference in the rostral network component versus control. A change in connectivity or functional volume is not itself a measurement of memory, attention, or cognitive performance.
Acute stress, behaviour, and early-life models
Other papers examine acute rat stress and consequences of early-life drug exposure. Neurochemical markers, pain sensitivity, and behaviour are separate outcomes. Findings in one model do not establish treatment of depression or anxiety, and absence of a behavioural effect should not be rewritten as improvement.
References
- Semax, an analogue of adrenocorticotropin
- Semax, an analog of ACTH(4−7), regulates expression of immune response genes during ischemic brain injury in rats
- Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia–Reperfusion
- The Peptide Drug ACTH(4–7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain
- Semax, synthetic ACTH(4–10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats
- Effects of Semax on the Default Mode Network of the Brain
- Audiogenic epilepsy in young mice of different strains after neonatal semax treatment
- Semax for Epilepsy Treatment
- Effects of Semax in the Rat Models of Acute Stress
- The Potency of Semax Peptide Therapy toward MDA Level and Protein Profile in Epilepsy Rats (Rattus norvegicus)
- SEMAX - APPLICATION PROSPECTS (brief overview message)
- Nootropic analogue of adrenocorticotropin 4-10-semax (the experience of design and investigation over 15 years)
Catalog of products presented for research activities. Not for human or veterinary use. This notice does not replace verification of applicable rules.